{
  "id": 9546242,
  "title": "Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)",
  "url": "https://urgent.news/2026/09/24/acadia-pharmaceuticals-announces-phase-3-enabling-topline-results",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-24T11:12:58.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/acadia-pharmaceuticals-announces-phase-3-enabling-topline-results-from-phase-2-radiant-study-of-remlifanserin-for-the-treatment-of-alzheimers-disease-psychosis-adp"
  },
  "original_language": "en",
  "account": null,
  "summary": "— Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect — Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077) — Favorable safety and tolerability profile across both […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Acadia drug fails mid-stage study in Alzheimer's psychosis, leading to modified Phase 3",
        "url": "https://urgent.news/2026/09/24/acadia-drug-fails-mid-stage-study-in-alzheimers-psychosis-leading-to",
        "published": "2026-09-24T14:50:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}